Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOPFOP saracatinib phase 2 trial in fibrodysplasia ossificans progressiva
NL-OMON56029Phase 2Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of saracatinib in fibrodysplasia ossificans progressiva (FOP) (3 arms), sponsored by Vrije University Medical Center. Primary endpoints: Incidence and severity of treatment-emergent adverse events and Change in number of new heterotopic bone lesions over 6 months. Started Aug 2020; status: recruiting.
02
Drugs
saracatinib
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NL-OMON56029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56029.